Long-Term Survival Outcomes With Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nat. Med. 2024 Jun 02;[EPub Ahead of Print], J Cortés, SA Hurvitz, SA Im, H Iwata, G Curigliano, SB Kim, JWY Chiu, JL Pedrini, W Li, K Yonemori, G Bianchini, S Loi, GS Borges, X Wang, T Bachelot, S Nakatani, S Ashfaque, Z Liang, A Egorov, E HamiltonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.